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Summary
Background:  Multimodal  analgesia  combining  several  non-opioid  analgesics  is  recommended  for
pain control  after  surgery.  In  one  study  of  total  hip  arthroplasty  (THA),  pain  relief  achieved  by
adding ketamine  to  the  paracetamol—ketoprofen  combination  was  statistically  signiﬁcant  but
remained inadequate  in  most  patients.  In  two  other  studies,  the  analgesic  effect  of  nefopam
was synergistic  with  that  of  ketoprofen  and  additive  with  that  of  paracetamol.  Adding  nefopam
to the  paracetamol—ketoprofen-ketamine  combination  has  not  been  evaluated.
Hypothesis:  Adding  nefopam  to  the  paracetamol—ketoprofen—ketamine  combination  signiﬁ-
cantly improves  analgesia  after  THA.
Material  and  methods:  A  prospective  single-centre  comparative  non-randomised  study  (control
group then  nefopam  group)  was  conducted  in  patients  undergoing  THA  under  general  anaes-
thesia. All  patients  received  paracetamol—ketoprofen—ketamine  and  morphine/droperidol
patient-controlled  analgesia.  The  nefopam  group  also  received  a  continuous  infusion  of  nefopam
(120 mg/d  for  48  h).  Pain  was  evaluated  daily  for  7  days.  The  main  evaluation  criteria  were  mor-
phine consumption,  and  pain  intensity  evaluated  using  a  numerical  rating  scale  and  a  validated
questionnaire.  To  detect  a  40%  morphine-sparing  effect  by  H24  ( =  0.05  and    =  0.2),  85  patients
were needed  in  each  group.
Results:  The  two  groups  (90  patients/group)  had  no  signiﬁcant  differences  for  perioperative
characteristics,  pain  scores,  morphine  consumption  at  H24  (nefopam,  13  ±  12  mg  and  control,
14 ±  13  mg,  P  =  0.39),  or  functional  recovery.  Compared  to  the  control  group,  the  nefopam  group
had lower  rates  of  nausea/vomiting  (P  <  0.0001),  pruritus  (P  =  0.002),  and  visual  disturbances
(P =  0.02).
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Discussion:  Nefopam  failed  to  improve  pain  relief  when  added  to  a  multimodal  analgesia  regi-
men but  alleviated  several  morphine-induced  side  effects.  Redundancy  between  nefopam  and
ketamine may  explain  the  absence  of  greater  pain  relief.  This  study  emphasises  the  need  for
clinical evaluations  of  every  analgesic  regimen,  as  the  available  data  were  not  sufﬁcient  to
predict these  results.
Level  of  evidence:  Level  III,  case-control  study.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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ffective  analgesia  is  crucial  to  expedite  and  improve  func-
ional  recovery  after  orthopaedic  surgery  [1].  Postsurgical
ehabilitation  can  be  adversely  affected  by  the  side  effects
f  opioids  (drowsiness,  respiratory  depression,  nausea,
omiting,  and  urinary  retention).  Most  of  these  side  effects
re  dose-dependent.  Multimodal  analgesia  seeks  to  decrease
heir  incidence  by  limiting  the  need  for  opioids.  Multimodal
nalgesia  consists  in  combining  several  non-opioid  analgesics
o  obtain  additive  or  even  synergistic  effects  [2].  However,
mong  combinations  of  non-opioid  drugs,  only  paraceta-
ol  plus  a  non-steroidal  anti-inﬂammatory  drug  (NSAID)  has
een  adequately  studied.
When  used  alone,  paracetamol,  nefopam,  and  keto-
rofen  have  a  morphine-sparing  effect  after  total  hip
rthroplasty  (THA)  [3—5]. The  paracetamol-NSAID  combi-
ation  has  been  proven  effective  [6—8]. Adding  ketamine
o  the  paracetamol—ketoprofen  combination  improved  pain
elief  after  THA,  for  up  to  6  months  [9].  Nevertheless,  most
f  the  patients  in  the  ketamine  add-on  group  reported
ersistent  moderate  to  severe  pain  (mean  maximum  pain
core  during  the  ﬁrst  3  days,  41  ±  28  mm)  and  41%  of  them
equired  anti-emetic  treatment  within  the  ﬁrst  24  h  after
urgery.  Thus,  further  optimisation  of  this  analgesia  proto-
ol  is  needed.  Nefopam  and  ketoprofen  act  synergistically
n  relieving  moderate  to  severe  pain  after  minor  surgery
10].  Adding  nefopam  to  paracetamol  decreases  the  mor-
hine  requirements  after  abdominal  surgery  [11]. However,
o  studies  have  evaluated  nefopam  added  to  ketamine  ther-
py.
The  objective  of  this  study  was  to  evaluate  the  effect  of
efopam  added  to  the  paracetamol—ketoprofen—ketamine
ombination  after  THA,  based  on  both  the  consumption  of
orphine  after  surgery  and  pain  intensity  measured  using  a
umerical  rating  scale  (NRS)  and  a  validated  questionnaire
9].  Our  hypothesis  was  that  adding  nefopam  improves  pain
ontrol  after  THA  and  decreases  morphine  requirements,
hereby  diminishing  morphine-induced  side  effects  such  as
ausea.
aterials and methods
atient  inclusionhe  research  project  was  approved  by  the  local  ethics
ommittee  (Comité  de  Protection  des  Personnes). Patients
cheduled  for  primary  THA  (regardless  of  the  surgical
pproach  and  type  of  prosthesis)  were  invited  to  participate
(
b
t
tn  the  study  during  the  pre-anaesthesia  evaluation.  At
ur  institution,  THA  is  performed  under  general  anaesthe-
ia.  Written  informed  consent  to  study  participation  was
btained  from  each  patient  on  the  day  before  surgery.
on-inclusion  criteria  were  surgery  for  cancer,  contraindica-
ions  to  nefopam  (acute  angle-closure  glaucoma,  epilepsy,
llergy,  nocturnal  frequency  with  more  than  two  bathroom
isits  per  night,  coronary  artery  disease),  contraindications
o  paracetamol  (liver  failure,  allergy),  contraindication  to
etamine  (porphyria),  chronic  morphine  use  in  a  daily
osage  greater  than  10  mg,  inability  to  understand  the  use
f  patient-controlled  analgesia  (PCA)  or  of  a  NRS  for  self-
valuating  pain  intensity,  and  refusal  to  participate.
We  used  a  prospective  controlled  design  with
wo  successive  enrolment  periods.  Between  Febru-
ry  2007  and  February  2008,  the  study  patients
eceived  the  control  treatment  regimen,  namely,
aracetamol—ketoprofen—ketamine.  During  the  sec-
nd  period,  from  February  to  November  2008,  nefopam
as  added  to  the  paracetamol—ketoprofen—ketamine
ombination.
naesthesia
uring  the  pre-anaesthesia  evaluation,  the  patients  were
nformed  about  the  use  of  PCA  and  about  pain  self-
valuation  using  the  NRS.  To  use  the  NRS,  the  patient
ated  pain  intensity  from  0  (no  pain)  to  100  (worst  pain
maginable).  Premedication  with  hydroxyzine  (100  mg)  or
lprazolam  (0.5  mg)  was  given  1  h  before  surgery.  General
naesthesia  was  induced  using  propofol  (2—3  mg/kg),  sufen-
anil  (0.3—0.5  g/kg),  and  atracurium  (0.5  mg/kg).  After
ral  endotracheal  intubation,  anaesthesia  was  maintained
sing  inhaled  sevoﬂurane/nitrous  oxide,  together  with  addi-
ional  sufentanil  and/or  atracurium  injections  as  needed.
he  patient  was  operated  on  in  the  lateral  decubitus  position
nder  a  hot  air  blanket.
nalgesia
etamine  was  injected  after  anaesthesia  induction  and
efore  the  incision  in  a  dose  of  0.5  mg/kg  (up  to  50  mg)
hen  given  as  a  continuous  intravenous  infusion  (2  mcg/kg
er  minute)  for  24  h,  through  a dedicated  line  in  a  three-way
xtension  tubing  with  anti-reﬂux  valves  [12]. Ketoprofen
50  mg)  and  paracetamol  (1  g)  were  injected  30—60  min
efore  closure  of  the  skin  incision  then  every  6  h.  Con-
raindications  to  ketoprofen  were  creatinine  clearance  (by
he  Cockcroft  formula)  lower  than  30  mL/min,  any  history
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of  gastric  or  duodenal  ulcer,  allergy,  and  NSAID-induced
asthma.  In  addition,  30—60  min  before  closure  of  the  skin
incision,  the  nefopam  group  patients  were  given  20  mg  of
nefopam  (Acupan®,  Biocodex,  Gentilly,  France)  over  30  min
followed  by  a  continuous  intravenous  infusion  for  48  h
(120  mg/d).  After  extubation  in  the  post-anaesthesia  care
unit  (PACU),  the  patients  used  the  NRS  to  evaluate  their
pain  intensity.  Patients  reporting  NRS  scores  greater  than
30  mm  received  intravenous  morphine  titration  (2—3  mg
every  5  min).  Once  the  NRS  score  fell  below  30  mm,  an
intravenous  PCA  device  was  set  up,  for  1  to  4  days  (bolus,
1  mg  every  7  min;  maximum,  15  mg/4  h;  no  continuous  infu-
sion).  The  device  was  loaded  with  100  mg  morphine  and
5  mg  droperidol.  Patients  with  nausea  were  given  a  4-mg
ondansetron  injection.
On  the  day  after  surgery,  the  oral  route  was  substituted
for  the  intravenous  route  for  paracetamol  (1  g  qid  until  dis-
charge)  and  ketoprofen  (150  mg  bid  for  24  h).  The  PCA  was
replaced  by  20  mg  oral  morphine  sulphate  as  needed  until
discharge.  The  patients  could  return  to  their  usual  analgesic
regimen  48  h  after  surgery,  at  their  request.
Thromboembolism  prophylaxis  was  with  2.5  mg/d  fonda-
parinux  injected  subcutaneously.  The  drains  were  removed
when  they  yielded  less  than  50  mL/d  and  on  the  third  postop-
erative  day  at  the  latest.  The  patient  was  then  encouraged
to  get  up  and,  on  the  next  day,  to  start  ambulating.
Study  parameters
For  each  patient,  we  collected  data  on  demographics  (age,
weight,  height,  co-morbidities,  preoperative  treatment),
the  anaesthesia  (doses  of  sufentanil,  ephedrine  or  atropine;
volume  of  crystalloids  and  colloids;  blood  transfusions;  body
temperature  at  completion  of  surgery;  duration  of  general
anaesthesia,  and  time  spent  in  the  PACU),  and  the  surgery
(whether  the  hip  osteoarthritis  was  primary  or  not,  history
of  surgery,  approach,  type  of  prosthesis,  whether  cement
was  used,  and  operative  time).
The  main  evaluation  criteria  were  morphine  consumption
and  pain  intensity.  Cumulative  morphine  consumption  during
the  ﬁrst  7  postoperative  days  was  computed  as  the  sum  of
the  dose  used  for  morphine  titration  in  the  PACU,  the  dose
delivered  by  PCA,  and  the  intravenous  equivalent  of  oral
morphine  doses  (10  mg  orally  =  3  mg  intravenously).  The  site
and  intensity  of  the  pain  were  evaluated  before  surgery,  in
the  PACU,  and  daily  thereafter  (in  the  morning  at  rest,  by
recording  the  maximal  pain  intensity  during  the  24-h  cycle;
at  ﬁrst  arising,  at  ﬁrst  ambulation,  and  at  discharge).  Pain
intensity  was  measured  using  the  NRS  and  questionnaires
used  in  a  previous  study  in  our  department  [9].
The  secondary  evaluation  criteria  were  functional  recov-
ery  assessed  on  the  7th  postoperative  day  based  on  time
to  ambulation,  leaving  the  room,  and  climbing  stairs;  side
effects  (experienced  at  least  once  by  the  patient)  were
reported  during  an  interview  at  the  bedside  on  the  7th  post-
operative  day  and  recorded  in  the  medical  chart.Statistics
Morphine  consumption  by  H24  was  14  ±  13  mg  in  a  previ-
ous  study  done  at  our  department  in  patients  receiving
w
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he paracetamol—ketoprofen—ketamine  combination  [9].  To
etect  a  40%  decrease  in  morphine  consumption  with  the
lpha  risk  set  at  0.05  and  80%  power,  we  needed  86  patients
n  each  group.  We  therefore  included  90  patients  per  group.
The  data  are  described  as  mean  ±  SD.  Quantitative  varia-
les  were  tested  using  Student’s  t  test  and  qualitative
ariables  using  the  Chi2 test  or  Fisher’s  test  (Statview  5.0
or  Windows,  SAS  Institute  Inc.,  Cary,  NC,  USA).  Values  of  P
ower  than  0.05  were  considered  signiﬁcant.
esults
f  the  378  patients  who  underwent  primary  THA  during
he  study  period,  198  were  excluded,  for  the  following
easons:  unwillingness  to  participate,  n  =  38;  participation
n  another  study,  n  =  110;  daily  use  of  opiates  or  drugs
ctive  against  neuropathic  pain,  n  =  20;  inability  to  use  the
CA  system,  n  =  19;  contraindication  to  nefopam  therapy,
 =  7;  porphyria,  n  =  3;  and  surgery  cancellation  (anaphy-
actic  shock  at  anaesthesia  induction),  n  =  1.  In  the  control
roup,  one  patient  required  repeat  surgery  at  H30  for  pros-
hesis  dislocation;  data  acquisition  was  stopped  at  H24  in
his  patient.  No  statistically  signiﬁcant  differences  were
ound  between  the  two  groups  regarding  the  preoperative
nd  intraoperative  characteristics  (Tables  1  and  2).
Morphine  consumption  by  H24  was  not  signiﬁcantly  dif-
erent  between  the  control  group  (13.8  ±  12.5  mg)  and
he  nefopam  group  (12.9  ±  11.9  mg)  (P  =  0.62)  (Table  3).
either  did  the  pain  scores  differ  signiﬁcantly  between
he  two  groups,  except  for  the  maximum  pain  intensity
core  in  the  PACU,  which  was  signiﬁcantly  lower  in  the
efopam  group  (17  ±  26  mm  versus  29  ±  31  mm  in  the  con-
rol  group,  P  =  0.007).  Signiﬁcantly  lower  rates  were  found  in
he  nefopam  group  for  ondansetron  use,  nausea,  vomiting,
ruritus,  and  visual  disturbances  (Table  4).
iscussion
his  study  shows  that  adding  nefopam  to  the
aracetamol—ketoprofen—ketamine  combination  has
o  signiﬁcant  effect  on  pain  intensity  or  morphine  con-
umption  after  THA.  Paradoxically,  nefopam  diminishes
everal  of  the  side  effects  of  morphine  therapy.
In  theory,  several  factors  might  have  masked  an  analgesic
ffect  of  nefopam  in  our  study.  One  is  the  non-randomised
tudy  design.  However,  the  two  groups  had  no  signiﬁcant
ifferences  for  multiple  preoperative  and  intraoperative
arameters  related  to  the  anaesthesia  and  surgical  pro-
edure.  The  higher  preoperative  use  of  analgesics  in  the
ontrol  group  might  have  spuriously  increased  analgesic  con-
umption  in  this  group.  Furthermore,  the  low  morphine
onsumption  in  the  control  group  made  it  difﬁcult  to  detect
 40%  decrease  in  morphine  use.  However,  the  study  was
esigned  to  ensure  that  a  40%  decrease  could  be  detected
ith  80%  power  and  5%  alpha  risk.  A  40%  decrease  was  per-
aps  an  excessively  ambitious  target.  Nevertheless,  a  30%
o  50%  decrease  in  morphine  consumption  has  been  reported
ith  nefopam  used  alone  [4,14]  or  combined  to  paracetamol
11].  We  hoped  to  obtain  a  greater  than  40%  decrease,  since
he  nefopam—ketoprofen  combination  has  been  associated
ith  a  16-fold  decrease  in  nefopam  dosage  requirements
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Table  1  Preoperative  features  in  the  two  groups  of  patients.
Control  group  (n  =  90)  Nefopam  group  (n  =  90)  P  value
Patients
Age  in  years,  mean  ±  SD  65  ±  13  65  ±  15  0.67
Body mass  index,  kg/m2,  mean  ±  SD  26.9  ±  4.5  26.7  ±  4.5  0.81
Body mass  index  >  30  kg/m2,  %  26  20  0.33
Male sex,  %  41  43  0.76
ASA III  score,  %  13  12  0.82
Previous surgery  on  same  hip,  % 20  9  0.06
Prosthesis on  contralateral  hip,  % 29 24  0.50
Characteristics  of  preoperative  pain
Pain  in  index  hip  at  rest,  NRS  score,  mean  ±  SD 45  ±  34 44  ±  31 0.85
Other pain  at  rest,  NRS  score,  mean  ±  SD  38  ±  34  29  ±  32  0.08
Pain in  index  hip  during  walking,  NRS  score,  mean  ±  SD  64  ±  26  61  ±  28  0.37
Other pain  during  walking,  NRS  score,  mean  ±  SD 41  ±  35  42  ±  34  0.88
Walking aid  needed,  % 54 43  0.12
Treatment for  chronic  pain
Antidepressant,  %  6  7  0.99
Benzodiazepine,  %  10  14  0.50
Non-steroidal  anti-inﬂammatory  drug,  %  44  38  0.36
Paracetamol,  %  70  40  <  0.0001
Codeine/dextropropoxyphene/tramadol,  %  41  27  0.04
NRS: numerical rating scale for pain intensity.
Table  2  Intraoperative  features  in  the  two  groups  of  patients.
Control  group  (n  =  90)  Nefopam  group  (n  =  90)  P  value
Anaesthesia
Duration  in  minutes,  mean  ±  SD  181  ±  41  174  ±  35  0.20
Total sufentanil  dose  in  /kg,  mean  ±  SD  1.03  ±  0.36  1.05  ±  0.33  0.80
Core temperature  at  surgery  completion  in ◦C,  mean  ±  SD  36.1  ±  0.6  35.9  ±  0.6  0.06
Patients given  ketoprofen,  %  86  86  0.99
Surgery
Diagnosis of  primary  hip  osteoarthritis,  %  68  69  0.87
THA on  the  left  hip,  %  44  46  0.88
Operative time  in  minutes,  mean  ±  SD  127  ±  37  123  ±  32  0.37
Approach: posterior/anterior/trochanterotomy,  %  40/49/10  47/51/2  0.08
Cemented femoral  component,  %  79  71  0.23
Cemented acetabular  component,  %  79  72  0.30
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nd  a  7-fold  decrease  in  ketoprofen  dosage  requirements,  as
ell  as  with  a  reduction  by  half  of  the  proportion  of  patients
aving  a  greater  than  30-mm  NRS  score  in  the  PACU  [10]. In
ur  nefopam  group,  86%  of  patients  received  ketoprofen.
Several  hypotheses  can  be  put  forward  to  explain  the
bsence  of  an  analgesic  effect  of  nefopam  in  our  study.
irst,  continuous  nefopam  administration  may  be  less  effec-
ive  than  a  30-min  intravenous  infusion.  Only  two  previous
tudies  found  no  analgesic  effect  of  nefopam,  and  both
sed  continuous  administration,  after  urological  surgery
15]  and  after  childbirth  [16], respectively.  This  factor  may
xplain  that  the  only  signiﬁcant  improvement  in  analge-
ia  in  the  nefopam  group  was  seen  in  the  PACU,  since  a
efopam  bolus  was  injected  at  the  end  of  the  surgical
k
i
srocedure.  Second,  the  analgesic  effect  of  ketamine  may
ave  masked  that  of  nefopam.  Two  comparative  studies
uggest  a  stronger  analgesic  effect  of  ketamine  compared
o  nefopam,  resulting  in  decreased  morphine  titration  in
he  PACU  (9  ±  5  vs.  10  ±  5  mg  after  major  surgery  [17]
nd  8  ±  5  vs.  11  ±  4  mg  after  total  knee  arthroplasty  [18])
nd,  above  all,  in  improved  functional  recovery  after  total
nee  arthroplasty  [18]. This  strong  effect  may  explain  that
dding  ketamine  to  the  paracetamol—nefopam  combination
mproved  analgesia  after  thoracotomy  [19], whereas  in  our
tudy  adding  nefopam  to  an  analgesic  combination  including
etamine  produced  no  further  analgesia  after  THA.  Exper-
mental  studies  suggest  that  this  effect  may  be  related  to
everal  similarities  in  the  mechanisms  of  action  of  the  two
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Table  3  Postoperative  pain  and  mobilisation.
Control  group  (n  =  90)  Nefopam  group  (n  =  90)  P  value
Patients  requiring  morphine  titration  in  the  PACU,  %  43  33  0.17
Morphine in  the  PACU  in  mg,  %  4.7  ±  6.6  3.6  ±  5.8  0.21
Highest NRS  score  in  mm  in  the  PACU,  mean  ±  SD  29  ±  31  17  ±  26  0.007
Total morphine  dose  in  mg  from  H0  to  H24,  mean  ±  SD  13.8  ±  12.5  12.9  ±  11.9  0.62
NRS score  in  mm  at  H24,  mean  ±  SD  15  ±  13  14  ±  15  0.68
Highest NRS  score  in  mm  between  H0  and  H24,  mean  ±  SD  26  ±  16  23  ±  14  0.12
Total morphine  dose  in  mg  from  H0  to  H48,  mean  ±  SD 18.6  ±  15.7  18.8  ±  18.0  0.94
NRS score  in  mm  at  H48,  mean  ±  SD 16  ±  16 12  ±  14 0.06
Highest NRS  score  in  mm  between  H24  and  H48,  mean  ±  SD 22  ±  13 19  ±  16 0.22
Total morphine  dose  in  mg  on  POD7,  mean  ±  SD 25.3  ±  24.0 27.9  ±  28.3 0.51
Highest NRS  score  in  mm  on  POD2,  mean  ±  SD 26  ±  18  26  ±  20  0.86
Highest NRS  score  in  mm  on  POD3,  mean  ±  SD  21  ±  15  24  ±  19  0.27
Highest NRS  score  in  mm  from  POD4  to  POD7,  mean  ±  SD  27  ±  17  27  ±  19  0.86
NRS score  during  walking  on  POD7,  mean  ±  SD  24  ±  22  24  ±  22  0.99
Time in  days  from  surgery  to  ﬁrst  ambulation,  mean  ±  SD  3.8  ±  3.3  3.9  ±  1.6  0.92
Able to  walk  up  and  down  stairs  on  POD7,  %  56  54  0.75
PACU: post-anaesthesia care unit; H: hour; POD: postoperative day; NRS: numerical rating scale for pain intensity.
Table  4  Postoperative  side  effects  between  POD0  and  POD7  (more  than  one  reported  episode).
Control  group
(n =  90)
Nefopam  group
(n  =  90)
P  value
Simpliﬁed  PONV  risk  according  to  Apfel  [13],  mean  ±  SD  50  ±  12  48  ±  14  0.44
Patients given  ondansetron  in  the  PACU,  %  29  4  <  0.0001
Patients given  ondansetron  from  PACU  discharge  to  H24,  %  26  14  0.09
Total patients  given  ondansetron  by  H24,  %  43  16  <  0.0001
Patients given  ondansetron  from  PACU  discharge  to  POD7,  %  31  20  0.09
Total patients  given  ondansetron  by  POD7 47  21  0.0003
Nausea/vomiting  reported  by  patients  from  PACU  discharge  to  POD7,  % 48 18  <  0.0001
Nausea from  PACU  discharge  to  POD7,  % 38 6 <  0.0001
Vomiting from  PACU  discharge  to  POD7,  % 28 13  0.02
Pruritus, % 19 3 0.002
Diplopia,  % 18 6 0.02
Urinary  retention  requiring  catheterisation,  % 9a 9 0.99
Nightmares,  % 19 9  0.08
Hallucinations,  % 6  11  0.19
a care
e ope
p
v
b
ﬁ
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t
tPONV: postoperative nausea and vomiting; PACU: post-anaesthesi
a Two patients excluded from the analysis (catheterisation in th
drugs,  both  of  which  inhibit  serotonin  reuptake  in  the  central
nervous  system,  thereby  enhancing  the  inhibitory  tone  of  the
descending  serotoninergic  spinal-cord  pathways  [20,21].
Paradoxically,  although  nefopam  failed  to  decrease  the
morphine  requirements  in  our  study,  it  diminished  several
morphine  side  effects  including  visual  disturbances,  pruri-
tus,  and  nausea/vomiting.  A  bias  related  to  an  abnormally
high  rate  of  these  side  effects  in  the  control  group  is  unlikely,
since  the  observed  rate  of  nausea/vomiting  was  consistent
with  that  predicted  by  the  Apfel  score  [13]  (Table  4).  Thus,
the  decrease  in  nausea  and  vomiting  seen  with  nefopam  may
be  ascribable  to  a  direct  effect  of  this  drug  rather  than  to
an  indirect  effect  mediated  by  a  decrease  in  morphine  con-
sumption,  with  the  anatomical  site  of  the  anti-emetic  effect
being  different  from  that  of  the  analgesic  effect.
D
T
c unit.
rating room).
This  study  shows  that  nefopam  added  to  the
aracetamol—ketoprofen—ketamine  combination  pro-
ides  no  additional  analgesia  after  THA.  Redundancy
etween  nefopam  and  ketamine  effects  may  explain  this
nding.  Nevertheless,  in  this  setting,  despite  the  absence
f  a  morphine-sparing  effect,  nefopam  decreased  some  of
he  side  effects  of  morphine.  This  unexpected  ﬁnding  needs
o  be  conﬁrmed  by  randomised  trials.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
1T
R
[
[
[
[
[
[
[
[
[
[
[74  
Funding:  Pôle  anesthésie  réanimation  SAMU,  Hôpital
rousseau,  CHRU  Tours,  Tours,  France.
eferences
[1] Bonnet F, Marret E. Postoperative pain management and
outcome after surgery. Best Pract Res Clin Anaesthesiol
2007;21:99—107.
[2] Buvanendran A, Kroin JS. Multimodal analgesia for con-
trolling acute postoperative pain. Curr Opin Anaesthesiol
2009;22:588—93.
[3] Peduto VA, Ballabio M, Stefanini S. Efﬁcacy of propacetamol in
the treatment of postoperative pain. Morphine-sparing effect
in orthopedic surgery. Italian Collaborative Group on Propac-
etamol. Acta Anaesthesiol Scand 1998;42:293—8.
[4] Du Manoir B, Aubrun F, Langlois M, et al. Randomized prospec-
tive study of the analgesic effect of nefopam after orthopaedic
surgery. Br J Anaesth 2003;91:836—41.
[5] Kostamovaara PA, Laitinen JO, Nuutinen LS, et al. Intravenous
ketoprofen for pain relief after total hip or knee replacement.
Acta Anaesthesiol Scand 1996;40:697—703.
[6] Hyllested M, Jones S, Pedersen JL, et al. Comparative effect
of paracetamol, NSAIDs or their combination in postopera-
tive pain management: a qualitative review. Br J Anaesth
2002;88:199—214.
[7] Romsing J, Moiniche S, Dahl JB. Rectal and parenteral
paracetamol, and paracetamol in combination with
NSAIDs, for postoperative analgesia. Br J Anaesth 2002;88:
215—26.
[8] Ong CKS, Seymour RA, Lirk P, et al. Combining paracetamol
(acetaminophen) with non-steroidal anti-inﬂammatory drugs:
a qualitative systematic review of analgesic efﬁcacy for acute
postoperative pain. Anesth Analg 2010;110:10.[9] Remerand F, Le Tendre C, Baud A, et al. The early and delayed
analgesic effects of ketamine after total hip arthroplasty:
a prospective, randomized, controlled, double-blind study.
Anesth Analg 2009;109:1963—71.
[F.  Remérand  et  al.
10] Delage N, Maaliki H, Beloeil H, et al. Median effective dose
(ED50) of nefopam and ketoprofen in postoperative patients:
a study of interaction using sequential analysis and isobolo-
graphic analysis. Anesthesiology 2005;102:1211—6.
11] Tramoni G, Viale JP, Cazals C, et al. Morphine-sparing effect of
nefopam by continuous intravenous injection after abdominal
surgery by laparotomy. Eur J Anaesthesiol 2003;20:990—2.
12] Remerand F, Couvret C, Pourrat X, et al. Prevention of
psychedelic side effects associated with low-dose continuous
intravenous ketamine infusion. Therapie 2007;62:499—505.
13] Apfel CC, Laara E, Koivuranta M, et al. A simpliﬁed risk score
for predicting postoperative nausea and vomiting: conclusions
from cross-validations between two centers. Anesthesiology
1999;91:693—700.
14] Mimoz O, Incagnoli P, Josse C, et al. Analgesic efﬁcacy
and safety of nefopam vs. propacetamol following hepatic
resection. Anaesthesia 2001;56:520—5.
15] Merle JC, Vandroux D, Odin I, et al. Analgesic effect of con-
tinuous intravenous nefopam after urological surgery. Ann Fr
Anesth Reanim 2005;24:13—8.
16] Ottmar K, Lepelletier D. Continuous intravenous nefopam for
analgesia in non-lactating women after cesarean section. Anes-
thesiology 2007;107:A1781.
17] Kapfer B, Alfonsi P, Guignard B, et al. Nefopam and ketamine
comparably enhance postoperative analgesia. Anesth Analg
2005;100:169—74.
18] Aveline C, Gautier JF, Vautier P, et al. Postoperative analgesia
and early rehabilitation after total knee replacement: a com-
parison of continuous low-dose intravenous ketamine versus
nefopam. Eur J Pain 2009;13:613—9.
19] Duale C, Sibaud F, Guastella V, et al. Perioperative ketamine
does not prevent chronic pain after thoracotomy. Eur J Pain
2009;13:497—505.
20] Fuller RW, Snoddy HD. Evaluation of nefopam as a
monoamine uptake inhibitor in vivo in mice. Neuro-
pharmacology 1993;32:995—9.
21] Martin LL, Bouchal RL, Smith DJ. Ketamine inhibits serotonin
uptake in vivo. Neuropharmacology 1982;21:113—8.
